Show simple item record

dc.contributor.authorSinger, Barry A
dc.contributor.authorAlroughani, Raed
dc.contributor.authorBrassat, David
dc.contributor.authorBroadley, Simon
dc.contributor.authorHartung, Hans-Peter
dc.contributor.authorHavrdova, Eva
dc.contributor.authorKim, Ho Jin
dc.contributor.authorOreja-Guevara, Celia
dc.contributor.authorPozzilli, Carlo
dc.contributor.authorSelmaj, Krzysztof W
dc.contributor.authorVermersch, Patrick
dc.contributor.authorWray, Sibyl
dc.contributor.authorMargolin, David H
dc.contributor.authorDaizadeh, Nadia
dc.contributor.authoret al.
dc.date.accessioned2021-03-17T03:56:27Z
dc.date.available2021-03-17T03:56:27Z
dc.date.issued2018
dc.identifier.issn1352-4585en_US
dc.identifier.urihttp://hdl.handle.net/10072/403216
dc.description.abstractBackground: In CARE-MS II (NCT00548405), 2 courses of alemtuzumab demonstrated significantly greater improvements on clinical outcomes vs SC IFNB-1a over 2 years (y) in patients (pts) with active RRMS and inadequate response to prior therapy. Alemtuzumab pts who were followed for a further 4 y in an extension study (NCT0090553) showed durable efficacy, even though most received no additional alemtuzumab or other disease-modifying therapy (DMT). In CARE-MS II, pts received 2 courses of alemtuzumab 12 mg/day (baseline: 5 days; 12 months [mo] later: 3 days); in the extension, pts could receive as-needed alemtuzumab retreatment (12 mg/day on 3 consecutive days; ≥12 mo after previous course for relapse or MRI activity) or another DMT (per investigator discretion). Pts completing the extension could enroll in the 5-y TOPAZ study (NCT02255656) for further long-term evaluation. Objectives: Evaluate efficacy and safety of alemtuzumab in CARE-MS II pts over 7 y. Methods: In TOPAZ, pts can receive alemtuzumab retreatment ≥12 mo after previous course or another DMT at any time (both per investigator discretion); MRI scans are done annually. Assessments included: annualized relapse rate (ARR); proportions of relapse-free pts; 6-mo confirmed disability worsening (CDW); 6-mo confirmed disability improvement (CDI); no evidence of disease activity (NEDA); adverse events (AEs). Results: 338/393 (86%) CARE-MS II alemtuzumab-treated pts who entered the extension remained on study until end of Y6. 336 then entered TOPAZ; 317 (94%) remained on study through Y7. Low ARR was maintained (0.14 at Y7). 87% of pts were relapse-free in Y7. Proportion of pts with stable or improved EDSS remained high (Y7: 73%). Through 7 y, 69% of pts were free of 6-mo CDW, 44% experienced 6-mo CDI, and the majority achieved NEDA in each year. These effects were achieved with 47% of pts receiving no further treatment (alemtuzumab or another DMT) after their initial 2 alemtuzumab courses. Incidences of most AEs, infusion-associated reactions, and infections decreased over time and were reduced vs the 2-y core study. Thyroid AE incidence peaked at Y3, then declined through Y7. Conclusion: Clinical efficacy of alemtuzumab was durable for 7 y in pts who had inadequate response to prior therapy, despite 47% receiving no further treatment since the initial 2 alemtuzumab courses. The majority of pts maintained low ARR, were relapse-free, showed stabilized or improved disability, and achieved NEDA in each year.en_US
dc.languageEnglishen_US
dc.publisherSage Publications Ltden_US
dc.publisher.urihttps://journals.sagepub.com/doi/full/10.1177/1352458517750967en_US
dc.relation.ispartofconferencenameACTRIMS Forumen_US
dc.relation.ispartofconferencetitleMultiple Sclerosis Journalen_US
dc.relation.ispartofdatefrom2018-02-01
dc.relation.ispartofdateto2018-02-03
dc.relation.ispartoflocationSan Diego, CA, USAen_US
dc.relation.ispartofpagefrom22en_US
dc.relation.ispartofpageto22en_US
dc.relation.ispartofissue1_supplen_US
dc.relation.ispartofvolume24en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchNeurosciencesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.fieldofresearchcode1109en_US
dc.subject.keywordsScience & Technologyen_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsClinical Neurologyen_US
dc.subject.keywordsNeurologyen_US
dc.titleDurable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Studyen_US
dc.typeConference outputen_US
dc.type.descriptionE3 - Conferences (Extract Paper)en_US
dcterms.bibliographicCitationSinger, BA; Alroughani, R; Brassat, D; Broadley, S; Hartung, H-P; Havrdova, E; Kim, HJ; Oreja-Guevara, C; Pozzilli, C; Selmaj, KW; Vermersch, P; Wray, S; Margolin, DH; Daizadeh, N; et al., Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study, Multiple Sclerosis Journal, 2018, 24, pp. 22-22en_US
dc.date.updated2021-03-17T03:52:58Z
gro.hasfulltextNo Full Text
gro.griffith.authorBroadley, Simon


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Conference outputs
    Contains papers delivered by Griffith authors at national and international conferences.

Show simple item record